✦ LIBER ✦

A phase III study of VP16 plus cisplatin (VP) alone or with ifosfamide (VIP) in previously untreated patients (pts) with extensive small cell carcinoma of the lung (SCLC): A hoosier oncology group trial

Book ID: 122080998
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 98 KB
Volume: 11
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(94)92150-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

266 A phase II study of VP-16 plus ifosf

266 A phase II study of VP-16 plus ifosfamide plus cisplatin (VIP) plus concurrent radiation therapy (XRT) for previously untreated limited small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) trial

✍ Sandler, A.B.; Ansari, R.; Fisher, W.; Gonin, R.; Levy, R.; Einhorn, L.H. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 163 KB

VP-16 and carboplatin in previously untr

VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group

✍ Evans, WK; Eisenhauer, E; Hughes, P; Maroun, JA; Ayoub, J; Shepherd, FA; Feld, R 📂 Article 📅 1988 🏛 Nature Publishing Group 🌐 English ⚖ 991 KB

A phase II trial of intravenous vinorelb

A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a southwest oncology group study

✍ Celestia S. Higano; John J. Crowley; Robert V. Veith; Robert B. Livingston 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 28 KB

Alternating chemotherapy with etoposide

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma : A Phase II trial of the North Central Cancer Treatment Group

✍ James R. Jett; Alan K. Hatfield; Shauna Hillman; Michael D. Bauman; James A. Mai 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 3 views

## Abstract ## BACKGROUND The objective of this study was to test the response rate and toxicity of alternating chemotherapy in previously untreated patients with extensive‐stage small cell lung carcinoma (SCLC). ## METHODS Patients with histologically proven, extensive‐stage SCLC, with a perfor

A phase II study of cisplatin, etoposide

A phase II study of cisplatin, etoposide, and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer: A Southwest Oncology Group trial

✍ Kelly, K; Bunn, P.A; Lovato, L; Crowley, J; Livingston, R.B; Gandara, D.R 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 116 KB

O-277 CALGB 9732: Final report of a rand

O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC)

✍ Niell, Harvey B.; Herndon, J.E.; Miller, A.A.; Watson, D.M.; Sandler, A.; Kelly, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 175 KB